Knockdown of VEGF receptor-1 (VEGFR-1) impairs macrophage infiltration, angiogenesis and growth of clear cell renal cell carcinoma (CRCC)

Cancer Biology and Therapy

Volumn 12, Issue 10, 2011, Pages 872-880

  Li, Chenghai ^a,c   Liu, Bin ^a,b   Dai, Zonghan ^a   Tao, Yunxia ^a  

^a TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^b HUNAN UNIVERSITY   (China)

^c HENAN PROVINCIAL CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

Author keywords

Angiogenesis; Angiogenic switch; Clear cell renal cell carcinoma (CRCC); Monocyte chemoattractant protein 1 (MCP 1); Tumor macrophage infiltration; Tumor specific therapy; VEGF receptor 1

Indexed keywords

MONOCYTE CHEMOTACTIC PROTEIN 1; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 1;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INHIBITION; CARCINOMA CELL; CELL INFILTRATION; CLEAR CELL CARCINOMA; CONTROLLED STUDY; FEMALE; GENE SILENCING; HUMAN; HUMAN CELL; KIDNEY CARCINOMA; MACROPHAGE; MOUSE; NONHUMAN; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; STROMA CELL; TUMOR NECROSIS; TUMOR XENOGRAFT;

ANIMALS; CARCINOMA, RENAL CELL; CELL LINE, TUMOR; CELL PROLIFERATION; CHEMOKINE CCL2; FEMALE; GENE KNOCKDOWN TECHNIQUES; HUMANS; KIDNEY NEOPLASMS; MACROPHAGES; MATRIX METALLOPROTEINASE 9; MICE; MICE, NUDE; NEOVASCULARIZATION, PATHOLOGIC; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1; VASCULAR ENDOTHELIAL GROWTH FACTORS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 81555210943     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.12.10.17672     Document Type: Article

References (44)

1. Kerbel RS. Tumor angiogenesis. N Engl J Med 2008; 358:872-880; PMID:18463380; http://dx.doi.org/10.1056/NEJMra0706596
2. Takahashi H, Shibuya M. The vascular endothelial growth factor (VEGF)/VEGF receptor system and its role under physiological and pathological conditions. Clin Sci 2005; 109:227-41; PMID:16104843; http://dx.doi.org/10.1042/ CS20040370
3. Rahimi N. VEGFR-1 and VEGFR-2: two nonidentical twins with a unique physiognomy. Front Biosci 2006; 11:818-29; PMID:16146773; http://dx.doi.org/10. 2741/1839
4. Al-Moundhri MS, Al-Shukaili A, Al-Nabhani M, Al-Bahrani B, Burney IA, Rizivi A, et al. Measurement of circulating levels of VEGF-A, -C, and -D and their receptors, VEGFR-1 and -2 in gastric adenocarcinoma. World J Gastroenterol 2008; 14:3879-83; PMID:18609713; http://dx.doi.org/10.3748/wjg.14.3879
5. Boiocchi L, Vener C, Savi F, Bonoldi E, Moro A, Fracchiolla NS, et al. Increased expression of vascular endothelial growth factor receptor correlates with VEGF and microvessel density in Philadelphia chromosome-negative myeloproliferative neoplasms. J Clin Pathol 2011; 64:226-31; PMID:21217153; http://dx.doi.org/10.1136/jcp.2010.083386
6. Kemik O, Sumer A, Sarbay A, Purisa S, Tuzun S. Circulating levels of VEGF family and their receptors in hepatocellular carcinoma. Bratisl Lek Listy 2010; 111:485-8; PMID:21180261
7. Rivet J, Mourah S, Murata H, Mounier N, Pisonero H, Mongiat-Artus P, et al. VEGF and VEGFR-1 are coexpressed by epithelial and stromal cells of renal cell carcinoma. Cancer 2008; 112:433-42; PMID: 18041056; http://dx.doi.org/10. 1002/cncr.23186
8. Klatte T, Seligson DB, LaRochelle J, Shuch B, Said JW, Riggs SB, et al. Molecular signatures of localized clear cell renal cell carcinoma to predict disease-free survival after nephrectomy. Cancer Epidemiol Biomarkers Prev 2009; 18:894-900; PMID:19240241; http://dx.doi.org/10.1158/1055-9965.EPI-08-0786
9. Soker S, Kaefer M, Johnson M, Klagsbrun M, Atala A, Freeman MR. Vascular endothelial growth factor-mediated autocrine stimulation of prostate tumor cells coincides with progression to a malignant phenotype. Am J Pathol 2001; 159:651-9; PMID:11485923; http://dx.doi.org/10.1016/S0002-9440(10)61736-1
10. Lesslie DP, Summy JM, Parikh NU, Fan F, Trevino JG, Sawyer TK, et al. Vascular endothelial growth factor receptor-1 mediates migration of human colorectal carcinoma cells by activation of Src family kinases. Br J Cancer 2006; 94:1710-7; PMID:16685275
11. Okita NT, Yamada Y, Takahari D, Hirashima Y, Matsubara J, Kato K, et al. Vascular endothelial growth factor receptor expression as a prognostic marker for survival in colorectal cancer. Jpn J Clin Oncol 2009; 39:595-600; PMID:19535387; http://dx.doi.org/10.1093/jjco/hyp066
12. Gerber HP, Condorelli F, Park J, Ferrara N. Differential transcriptional regulation of the two vascular endothelial growth factor receptor genes. Flt-1, but not Flk-1/KDR, is up-regulated by hypoxia. J Biol Chem 1997; 272:23659-67; PMID:9295307; http://dx.doi.org/10.1074/jbc.272.38.23659
13. Kaplan RN, Riba RD, Zacharoulis S, Bramley AH, Vincent L, Costa C, et al. VEGFR1-positive haematopoietic bone marrow progenitors initiate the premetastatic niche. Nature 2005; 438:820-7; PMID: 16341000; http://dx.doi.org/10.1038/nature04186
14. Frank NY, Schatton T, Kim S, Zhan Q, Wilson BJ, Ma J, et al. VEGFR-1 expressed by malignant melanoma initiating cells is required for tumor growth. Cancer Res 2011; 71:1474-85; PMID: 21212411; http://dx.doi.org/10.1158/0008- 5472.CAN-10-1660
15. van Houwelingen KP, van Dijk BA, Hulsbergen-van de Kaa CA, Schouten LJ, Gorissen HJ, Schalken JA, et al. Prevalence of von Hippel-Lindau gene mutations in sporadic renal cell carcinoma: results from The Netherlands cohort study. BMC Cancer 2005; 5:57; PMID: 15932632; http://dx.doi.org/10.1186/1471-2407-5-57
16. Igarashi H, Esumi M, Ishida H, Okada K. Vascular endothelial growth factor overexpression is correlated with von Hippel-Lindau tumor suppressor gene inactivation in patients with sporadic renal cell carcinoma. Cancer 2002; 95:47-53; PMID:12115316; http://dx.doi.org/10.1002/cncr.10635
17. Guo Y, Higazi AA, Arakelian A, Sachais BS, Cines D, Goldfarb RH, et al. A peptide derived from the nonreceptor binding region of urokinase plasminogen activator (uPA) inhibits tumor progression and angiogenesis and induces tumor cell death in vivo. FASEB J 2000; 14:1400-10; PMID:10877833; http://dx.doi.org/10.1096/fj.14.10.1400
18. Baccala A, Jr., Hedgepeth R, Kaouk J, Magi-Galluzzi C, Gilligan T, Fergany A. Pathological evidence of necrosis in recurrent renal mass following treatment with sunitinib. Int J Urol 2007; 14:1095-7; PMID:18036049; http://dx.doi.org/10.1111/j.1442-2042.2007.01902.x
19. Ferrara N. VEGF-A: a critical regulator of blood vessel growth. Eur Cytokine Netw 2009; 20:158-63; PMID:20167554
20. Johnson C, Sung H-J, Lessner SM, Fini ME, Galis ZS. Matrix metalloproteinase-9 is required for adequate angiogenic revascularization of ischemic tissues. Potential role in capillary branching. Circ Res 2004; 94:262-8; PMID:14670843; http://dx.doi.org/10.1161/01.RES.0000111527.42357.62
21. Coussens LM, Tinkle CL, Hanahan D, Werb Z. MMP-9 supplied by bone marrow-derived cells contributes to skin carcinogenesis. Cell 2000; 103:481-90; PMID:11081634; http://dx.doi.org/10.1016/S0092-8674(00)00139-2
22. Coffelt SB, Hughes R, Lewis CE. Tumor-associated macrophages: Effectors of angiogenesis and tumor progression. Biochim Biophys Acta 2009; 1796:11-8; PMID:19269310
23. Toge H, Inagaki T, Kojimoto Y, Shinka T, Hara I. Angiogenesis in renal cell carcinoma: the role of tumor-associated macrophages. Int J Urol 2009; 16:801-7; PMID:19811548; http://dx.doi.org/10.1111/j.1442-2042.2009.02377.x
24. Lewis JS, Landers RJ, Underwood JC, Harris AL, Lewis CE. Expression of vascular endothelial growth factor by macrophages is up-regulated in poorly vascularized areas of breast carcinomas. J Pathol 2000; 192:150-8; PMID:11004690; http://dx.doi.org/10.1002/1096- 9896(2000)9999:9999<::AID- PATH687>3.0.CO;2-G
25. Hagemann T, Wilson J, Burke F, Kulbe H, Li NF, Pluddemann A, et al. Ovarian cancer cells polarize macrophages toward a tumor-associated phenotype. J Immunol 2006; 176:5023-32; PMID:16585599
26. Wang R, Zhang J, Chen S, Lu M, Luo X, Yao S, et al. Tumor-associated macrophages provide a suitable microenvironment for non-small lung cancer invasion and progression. Lung Cancer 2011. In press. PMID:21601305; http://dx.doi.org/10.1016/j.lungcan.2011.04.009
27. Belotti D, Calcagno C, Garofalo A, Caronia D, Riccardi E, Giavazzi R, et al. Vascular Endothelial Growth Factor Stimulates Organ-Specific Host Matrix Metalloproteinase-9 Expression and Ovarian Cancer Invasion. Mol Cancer Res 2008; 6:525-34; PMID:18403633; http://dx.doi.org/10.1158/1541-7786.MCR-07-0366
28. Mantovani A, Allavena P, Sozzani S, Vecchi A, Locati M, Sica A. Chemokines in the recruitment and shaping of the leukocyte infiltrate of tumors. Semin Cancer Biol 2004; 14:155-60; PMID:15246050; http://dx.doi.org/10.1016/j. semcancer.2003.10.001
29. Black WC, Welch HG. Advances in diagnostic imaging and overestimations of disease prevalence and the benefits of therapy. N Engl J Med 1993; 328:1237-43; PMID:8464435; http://dx.doi.org/10.1056/NEJM199304293281706
30. Almog N. Molecular mechanisms underlying tumor dormancy. Cancer Lett 2010; 294:139-46; PMID:20363069; http://dx.doi.org/10.1016/j.canlet.2010.03.004
31. Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet 2001; 357:539-45; PMID:11229684; http://dx.doi.org/10.1016/S0140-6736(00)04046- 0
32. Ramanathan M, Giladi A, Leibovich SJ. Regulation of vascular endothelial growth factor gene expression in murine macrophages by nitric oxide and hypoxia. Exp Biol Med (Maywood) 2003; 228:697-705; PMID:12773701
33. Harmey JH, Dimitriadis E, Kay E, Redmond HP, Bouchier-Hayes D. Regulation of macrophage production of vascular endothelial growth factor (VEGF) by hypoxia and transforming growth factor beta-1. Ann Surg Oncol 1998; 5:271-8; PMID:9607631; http://dx.doi.org/10.1007/BF02303785
34. Gazzaniga S, Bravo AI, Guglielmotti A, van Rooijen N, Maschi F, Vecchi A, et al. Targeting Tumor-Associated Macrophages and Inhibition of MCP-1 Reduce Angiogenesis and Tumor Growth in a Human Melanoma Xenograft. J Invest Dermatol 2007; 127:2031-41; PMID:17460736; http://dx.doi.org/10.1038/sj.jid.5700827
35. Ohta M, Kitadai Y, Tanaka S, Yoshihara M, Yasui W, Mukaida N, et al. Monocyte chemoattractant protein-1 expression correlates with macrophage infiltration and tumor vascularity in human esophageal squamous cell carcinomas. Int J Cancer 2002; 102:220-4; PMID:12397639; http://dx.doi.org/10.1002/ijc. 10705
36. Ohta M, Kitadai Y, Tanaka S, Yoshihara M, Yasui W, Mukaida N, et al. Monocyte chemoattractant protein-1 expression correlates with macrophage infiltration and tumor vascularity in human gastric carcinomas. Int J Oncol 2003; 22:773-8; PMID:12632067
37. van Ravenswaay Claasen HH, Kluin PM, Fleuren GJ. Tumor infiltrating cells in human cancer. On the possible role of CD16+ macrophages in antitumor cytotoxicity. Lab Invest 1992; 67:166-74; PMID:1501443
38. Lewis CE, Pollard JW. Distinct role of macrophages in different tumor microenvironments. Cancer Res 2006; 66:605-12; PMID:16423985; http://dx.doi.org/10.1158/0008-5472.CAN-05-4005
39. Yang JC, Haworth L, Sherry RM, Hwu P, Schwartzentruber DJ, Topalian SL, et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003; 349:427-34; PMID:12890841; http://dx.doi.org/10.1056/NEJMoa021491
40. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007; 356:115-24; PMID:17215529; http://dx.doi.org/10.1056/NEJMoa065044
41. Murphy EA, Majeti BK, Barnes LA, Makale M, Weis SM, Lutu-Fuga K, et al. Nanoparticle-mediated drug delivery to tumor vasculature suppresses metastasis. Proc Natl Acad Sci USA 2008; 105:9343-8; PMID:18607000; http://dx.doi.org/10. 1073/pnas.0803728105
42. Rakic JM, Lambert V, Devy L, Luttun A, Carmeliet P, Claes C, et al. Placental growth factor, a member of the VEGF family, contributes to the development of choroidal neovascularization. Invest Ophthalmol Vis Sci 2003; 44:3186-93; PMID:12824270; http://dx.doi.org/10.1167/iovs.02-1092
43. Tao Y, Kim J, Yin Y, Zafar I, Falk S, He Z, et al. VEGF receptor inhibition slows the progression of polycystic kidney disease. Kidney Int 2007; 72:1358-66; PMID: 17882148; http://dx.doi.org/10.1038/sj.ki.5002550
44. Sun X, Li C, Zhuang C, Gilmore WC, Cobos E, Tao Y, et al. Abl interactor 1 regulates Src-Id1-matrix metalloproteinase 9 axis and is required for invadopodia formation, extracellular matrix degradation and tumor growth of human breast cancer cells. Carcinogenesis 2009; 30:2109-16; PMID:19843640; http://dx.doi.org/10.1093/carcin/bgp251